About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Novartis Chip Implant Texts Your Phone When You Need Another Pill

By Jim Edwards | Sep 22, 2009

Novartis implanted computer chips into the shoulders of 20 patients taking the blood pressure drug Diovan; the chips sent text messages to their cellphones when it was time to take the next pill. The experiment was designed to improve “compliance.” (Lousy compliance is the phenomenon of patients receiving prescriptions but not filling or taking them — thus costing Big Pharma sales.)

The development will be sure to horrify conspiracy theorists, civil libertarians, privacy activists, paranoid schizophrenics and anyone else who does not want a computer chip monitored by a multinational drug company inserted into their body.

Novartis’ efforts are doubly creepy because it actually involves two internal chips. The first chip is inside the pill being swallowed. It sends a signal to the chip in your shoulder. If you fail to take your next pill, the shoulder chip nags you on your mobile. Note that after the text arrives on your phone, the message then goes “onto the internet for caregivers to review and analyze.”

Creepiest of all? It works, according to the FT:

Joe Jimenez, head of pharmaceuticals at Novartis, said tests using the system – which broadcasts from the “chip in the pill” to a receiver on the shoulder – on 20 patients using Diovan, a drug to lower blood pressure, had boosted “compliance” with prescriptions from 30 per cent to 80 per cent after six months.

And finally: “Pfizer’s Health Solutions division has developed a system to telephone patients to encourage them to take medicine,” the FT notes.

Bonus: Could the next step for drug companies be a version of ED 209 from the movie Robocop? If you don’t take your pill, he shows up in your house and gives you 20 seconds to comply. See video.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Waiting for New Novartis HBP Drug

    Seeking Alpha - 53 days 20 hours 5 minutes ago

    Zacks.com submits: Novartis NVS is expected to launch its high blood pressure drug Valturna shortly after the recent US Food and Drug Administration approval. The drug is a single-pill combination of Diovan valsartan, an angiotensin receptor blocker and Tekturna aliskiren, the only approved direct renin inhibitor. We believe

  • New Tekturna HCT approval in the US

    Scrip News - 122 days 13 hours 58 minutes ago

    The US FDA has approved Novartis's combination antihypertensive Tekturna HCT (aliskiren and hydrochlorothiazide) for first-line use in patients who are likely to need more than one drug therapy to control their blood pressure. The dual

  • US FDA approves Novartis's hypertension drug combo, Valturna

    Scrip News - 63 days 12 hours 28 minutes ago

    The US FDA has given the green light to Novartis's combination high blood pressure drug Valturna (valsartan plus aliskiren). It is indicated as a first-line treatment for patients likely to need multiple drugs to achieve their blood

  • Novartis profit jumps, but foresees tougher 2009

    Globe and Mail - 296 days 5 hours 3 minutes ago

    Swiss drug maker Novartis AG expects 2009 to be increasingly tough, even after sales of blood pressure and cancer drugs helped drive fourth-quarter profit up 62 per cent to $1.5-billion (U.S.). Novartis said yesterday it expected 2009 to be "increasingly challenging." The company faces looming loss of patent protection for its top-selling Diovan...

  • Drug sales drive Novartis profits

    BBC - 296 days 20 hours 21 minutes ago

    Novartis, the Swiss pharmaceuticals giant, has reported strong growth in full year profits, driven by sales of blood-pressure and cancer drugs. Net profit for 2008 jumped 24.8%, from $6.54bn (£4.6bn) in 2007 to $8.16bn. Year-on-year net profits in the three months to December, when the global economy moved towards recession, grew by 62%, from...

 
Reply to Story

BNET TalkbackShare your ideas and expertise on this topic

Subscribe to this discussion via Email or RSS

  •  
    1

    BeverlyMurray

    09/23/09 | Report as spam

    RE: Novartis Chip Implant Texts Your Phone When You Need Another Pill

    Whereas there can be abuse with any valued innovation, I applaud the possibilities of this approach. In particular, I see great benefit for those persons whose lives are regularly interrupted with the need to monitor and dose or simply remember to take a med to avoid complications.

  •  
    2

    shane@...

    09/23/09 | Report as spam

    RE: Novartis Chip Implant Texts Your Phone When You Need Another Pill

    Your ?Big Brother? and ?Compliance is all about sales? slants to this story of course leave out the fact that THE major barrier to control of blood pressure is making sure the effective medicines we have are taken properly. The likelihood of long term healthful outcomes for these patients may depend on compliance programs or tools that can help them overcome behavioral hurdles that prevent consistent control of their life endangering condition. To simply write off the Novartis experiments as ?scary? turns your column into simple cynicism. Sure, pharma stands to benefit from improved compliance, but in the case of blood pressure and many other conditions, I am going to applaud both their increased sales and the improvements they deliver for patients when they are successful. I read your MANY stories about unethical or illegal practices and believe that exposing these bottom feeders is helpful in reaching the goal of improving our industry. In this case you have confused an attempt to explore valuable progress with the other abuses you write about so often.

  •  
    3

    patrons99

    10/02/09 | Report as spam

    RE: Novartis Chip Implant Texts Your Phone When You Need Another Pill

    No Thanks! I don?t want any part of Novartis? and Pfizer?s vision of the future. Their chip implants are a violation of some of our most fundamental rights as citizens...those of autonomy, choice, privacy, and personal control over what our bodies are exposed too. The pharma mantra of ?unfettered access? to the ?world?s best drugs? is only a heartbeat away from government mandates. There must be a system of checks and balances to this particularly unscrupulous example of corporate ?innovation? at any cost, including and not limited to actual physical intrusions upon our bodies. Let the public weigh in.

  •  
    4

    Rocky Mountain Man

    10/11/09 | Report as spam

    David

    "Conspiracy theorists" will worry? With things like this happening how can you, in good conscience, silence free speech by using the term "conspiracy theorist?"

    In fact, these totalitarian and treasonous behaviors prove that these are not theories but that they are facts. Who needs theories? These kinds of things prove that many many "people" in the U.S. have no respect whatsoever for their fellow Americans, their God-given natural rights, and the governments promise to do what a legitimate government does and an illegitimate government doesn't do, guarantee our natural rights. This technology and the traitors and psychopaths who promote it is proof that the claims of traitors depriving us of our rights are a fact not a theory.

    In short, it is ridiculous to show a gross violation of our right of epic proportions and then say that "conspiracy theorists" will worry!

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement